Fig. 1 · Structure

Documents & Downloads

Buflomedil HCl

Cat. No. A11737 CAS 35543-24-9

VEGFR Antagonist

Buflomedil is a vasoactive agent used to treat peripheral vascular disease.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Buflomedil HCl Research Summary

This section summarizes 1 in vivo study of Buflomedil HCl from 1 published reference.

Buflomedil HCl In Vivo Studies

Buflomedil was administered intraperitoneally to male Syrian golden hamsters before skin flap preparation and postoperatively in the McFarlane skin flap model. The percentage of viable areas did not differ among the control, Buflomedil, and pentoxifylline groups. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Buflomedil in a hamster skin flap model

Animal study · male 10-week-old Syrian golden hamsters; McFarlane skin flap model [1]

Male Syrian golden hamsters in the McFarlane skin flap model received Buflomedil intraperitoneally before skin flap preparation and postoperatively. The percentage of viable areas did not differ among the control, Buflomedil, and pentoxifylline groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of viable area (%VA); on the seventh post-operative dayReported result 3 mg/kg/day of buflomedil; on the seventh post-operative day: there was no difference in the percentage of viable areas among the control, buflomedil, and pentoxifylline groups (50.7, 52.9, and 47.0, respectively).[1]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
1 hour before skin flap preparation and for 7 days post-operatively at 12-hour intervals
Vehicle
0.9% NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Buflomedil 3 mg/kg/dayThe control group received 0.1 ml of vehicle (C, 0.9% NaCl)3 mg/kg/day of buflomedil; on the seventh post-operative day: there was no difference in the percentage of viable areas among the control, buflomedil, and pentoxifylline groups (50.7, 52.9, and 47.0, respectively).[1]
Buflomedil 3 mg/kg/day
Model: male 10-week-old Syrian golden hamsters; McFarlane skin flap model
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Buflomedil

The paper names Buflomedil without stating the salt or form; not verified as the hydrochloride form supplied as A11737. No dose conversion or lot validation.

MATERIALS AND METHODS (S1, S3, S4, S11); MATERIALS AND METHODS > Parameters Evaluated > Percentage of viable skin flap area (%VA) (S22); RESULTS (S35)

percentage of viable area (%VA); on the seventh post-operative day: percentage of viable area (%VA); on the seventh post-operative day; comparator: The control group received 0.1 ml of vehicle (C, 0.9% NaCl) — MATERIALS AND METHODS (S3); MATERIALS AND METHODS > Parameters Evaluated > Percentage of viable skin flap area (%VA) (S22); RESULTS (S35)

Buflomedil 3 mg/kg/day · MATERIALS AND METHODS (S3, S4); MATERIALS AND METHODS > Parameters Evaluated > Percentage of viable skin flap area (%VA) (S22); RESULTS (S35)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 35543-24-9
Applications VEGFR Antagonist
Formula C17H25NO4.HCl
Molecular Weight 343.85
SMILES
COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 28 mg/mL (81.43 mM)
Water 62 mg/mL (180.3 mM)
Ethanol 6 mg/mL (17.44 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Buflomedil HCl Research References

  1. [1] Coelho da Mota DS, Furtado E, Bottino DA, et al. Effects of buflomedil and pentoxifylline on hamster skin-flap microcirculation: prediction of flap viability using orthogonal polarization spectral imaging. Clinics (Sao Paulo) (2009). PMID: 19690666 DOI: 10.1590/S1807-59322009000800015 Source material

Added to your cart

View Cart Checkout
Loading...